Публикации для специалистов

ANDROGEN-DEPRIVATION THERAPY AS PRIMARY TREATMENT FOR LOCALIZED PROSTATE CANCER
17.11.2010
Prostate cancer is largely an androgen-sensitive disease. Androgendeprivation therapy (ADT) generally has been used for patients with advanced disease. However, ADT is used increasingly as monotherapy for patients with clinically localized disease. The objective of the current report was to describe the characteristics of patients who underwent ADT for the management of localized disease.
BRACHYTHERAPY FOR PROSTATE CANCER: A SYSTEMATIC REVIEW
29.10.2010
Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients.
LATE RECTAL COMPLICATIONS AFTER PROSTATE BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER
27.10.2010
Prostate cancer is the leading cause of cancer in men and accounts for approximately 33% of cancer deaths among men in the US.1,2 Management options for organ-confined, low- to intermediate-risk prostate cancer include watchful waiting, radical prostatectomy, external-beam radiation therapy, and prostate brachytherapy with permanent interstitial implants.
Расчет рисков для радикальных методов лечения рака предстательной железы.
22.10.2010
Расчет рисков для радикальных методов лечения рака предстательной железы.
11 25 IMPLANT OF THE PROSTATE
21.10.2010
Retropubic 1-125 implantation of the prostate at the time of suprapubic extraperitoneal pelvic lymphadenectomy is a well-established method of treatment for stages B2 and early C prostatic cancer.
10 YEARS 1
15.10.2010
lication in Cancer in June 1997. The article written by Giacalone et al. appeared in September 19964 but was not referenced through MEDLINE at the time we were preparing our article. We occasionally have noted a delay in the entry of case reports and research letters to the MEDLINE database. As an example, one of our articles was published in the February 1998 issue of The Lancet,5 but did not appear in the MEDLINE database until October 1998.
ГИГИЕНИЧЕСКИЕ ТРЕБОВАНИЯ ПО ОБЕСПЕЧЕНИЮ РАДИАЦИОННОЙ БЕЗОПАСНОСТИ ПРИ ВНУТРИТКАНЕВОЙ ЛУЧЕВОЙ ТЕРАПИИ (БРАХИТЕРАПИИ) МЕТОДОМ ИМПЛАНТАЦИИ ЗАКРЫТЫХ РАДИОНУКЛИДНЫХ ИСТОЧНИКОВ
09.09.2010
Гигиенические требования по обеспечению радиационной безопасности при внутритканевой лучевой терапии (брахитерапии) методом имплантации закрытых радионуклидных источников. Методические указания.
АНАЛИЗ ПОКАЗАНИЙ К ВЫПОЛНЕНИЮ БРАХИТЕРАПИИ У БОЛЬНЫХ ЛОКАЛИЗОВАННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
21.05.2010
Низкодозная брахитерапия является современным методом лечения локализованного рака предстательной железы, сопоставимым по эффективности с радикальной простатэктомией и дистанционной лучевой терапией. В клинике урологии МГМСУ внедрены различные методы лечения этой группы больных
ИНТЕРСТИЦИАЛЬНАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ЛОКАЛИЗОВАННЫХ ФОРМ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
21.05.2010
Большое значение имеет выявление заболевания на ранней стадии, лечение которых возможно малоинвазивными методами, не требующими много времени и огромных материальных затрат.
HEALTH-RELATED QUALITY OF LIFE UP TO SIX YEARS AFTER(125) I BRACHYTHERAPY FOR EARLY-STAGE PROSTATE CANCER
15.05.2010
Although a statistically significant change between 6 years after treatment and baseline was seen for some HRQOL items, most changes were not clinically relevant. A statistically significant deterioration was seen for urinary symptoms, bowel symptoms, pain, physical functioning, and sexual activity.